Non-disclosure of HIV testing history in population-based surveys: implications for estimating a UNAIDS 90-90-90 target by Rentsch, Christopher T et al.
Rentsch, Christopher T; Reniers, Georges; Machemba, Richard; Slay-
maker, Emma; Marston, Milly; Wringe, Alison; Eaton, Jeffrey W;
Gourlay, Annabelle; Rice, Brian; Kabudula, Chodziwadziwa White-
son; Urassa, Mark; Todd, Jim; Zaba, Basia (2018) Non-disclosure of
HIV testing history in population-based surveys: implications for es-
timating a UNAIDS 90-90-90 target. GLOBAL HEALTH ACTION,
11 (1). ISSN 1654-9880 DOI: https://doi.org/10.1080/16549716.2018.1553470
Downloaded from: http://researchonline.lshtm.ac.uk/4650753/
DOI: 10.1080/16549716.2018.1553470
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=zgha20
Global Health Action
ISSN: 1654-9716 (Print) 1654-9880 (Online) Journal homepage: http://www.tandfonline.com/loi/zgha20
Non-disclosure of HIV testing history in
population-based surveys: implications for
estimating a UNAIDS 90-90-90 target
Christopher T. Rentsch, Georges Reniers, Richard Machemba, Emma
Slaymaker, Milly Marston, Alison Wringe, Jeffrey W. Eaton, Annabelle
Gourlay, Brian Rice, Chodziwadziwa Whiteson Kabudula, Mark Urassa, Jim
Todd & Basia Żaba
To cite this article: Christopher T. Rentsch, Georges Reniers, Richard Machemba, Emma
Slaymaker, Milly Marston, Alison Wringe, Jeffrey W. Eaton, Annabelle Gourlay, Brian Rice,
Chodziwadziwa Whiteson Kabudula, Mark Urassa, Jim Todd & Basia Żaba (2018) Non-disclosure
of HIV testing history in population-based surveys: implications for estimating a UNAIDS 90-90-90
target, Global Health Action, 11:1, 1553470, DOI: 10.1080/16549716.2018.1553470
To link to this article:  https://doi.org/10.1080/16549716.2018.1553470
© 2018 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group.
View supplementary material 
Published online: 14 Dec 2018. Submit your article to this journal 
Article views: 66 View Crossmark data
ORIGINAL ARTICLE
Non-disclosure of HIV testing history in population-based surveys:
implications for estimating a UNAIDS 90-90-90 target
Christopher T. Rentsch a, Georges Reniersa,b, Richard Machembac, Emma Slaymaker a, Milly Marston a,
Alison Wringea, Jeffrey W. Eatond, Annabelle Gourlaya, Brian Ricee, Chodziwadziwa Whiteson Kabudulab,
Mark Urassac, Jim Todda,c and Basia Żabaa
aDepartment of Population Health, London School of Hygiene & Tropical Medicine, London, UK; bMRC/Wits Rural Public Health and
Health Transitions Research Unit (Agincourt), School of Public Health, Faculty of Health Sciences, University of the Witwatersrand,
Johannesburg, South Africa; cThe TAZAMA Project, National Institute for Medical Research, Mwanza, Tanzania; dDepartment of
Infectious Disease Epidemiology, Imperial College London, London, UK; eDepartment of Social and Environmental Health Research,
London School of Hygiene & Tropical Medicine, London, UK
ABSTRACT
Background: HIV/AIDS programmes and organisations around the world use routinely
updated estimates of the UNAIDS 90-90-90 targets to track progress and prioritise further
programme implementation. Any bias in these estimates has the potential to mislead
organisations on where gaps exist in HIV testing and treatment programmes.
Objective: To measure the extent of undisclosed HIV testing history and its impact on
estimating the proportion of people living with HIV (PLHIV) who know their HIV status (the
‘first 90’ of the UNAIDS 90-90-90 targets).
Methods: We conducted a retrospective cohort study using population-based HIV serological
surveillance conducted between 2010 and 2016 and linked, directly observed HIV testing
records in Kisesa, Tanzania. Generalised estimating equations logistic regression models were
used to detect associations with non-disclosure of HIV testing history adjusting for demo-
graphic, behavioural, and clinical characteristics. We compared estimates of the ‘first 90’ using
self-reported survey data only and augmented estimates using information from linked
records to quantify the absolute and relative impact of undisclosed HIV testing history.
Results: Numbers of participants in each of the survey rounds ranged from 7171 to 7981 with
an average HIV prevalence of 6.9%. Up to 33% of those who tested HIV-positive and 34% of
those who tested HIV-negative did not disclose their HIV testing history. The proportion of
PLHIV who reported knowing their status increased from 34% in 2010 to 65% in 2016.
Augmented estimates including information from directly observed testing history resulted
in an absolute impact of 6.7 percentage points and relative impact of 12.4%.
Conclusions: In this population, self-reported testing history in population-based HIV sero-
logical surveys under-estimated the percentage of HIV positives that are diagnosed by a
relative factor of 12%. Research should be employed in other surveillance systems that
benefit from linked data to investigate how bias may vary across settings.
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Background
The effectiveness of HIV testing and counselling
(HTC) services is principally measured by the num-
ber of people living with HIV (PLHIV) who know
their HIV status [1]. These services are the gateway to
receiving further HIV prevention, care, and treatment
services. In 2014, the Joint United Nations
Programme on HIV/AIDS (UNAIDS) launched a
series of targets known as ‘90-90-90’, which stated
that by 2020, 90% of all PLHIV will be diagnosed
(the ‘first 90’), 90% of people diagnosed with HIV will
receive antiretroviral treatment (ART) (the ‘second
90’), and 90% of people receiving ART will achieve
viral suppression (the ‘third 90’) [2]. Routinely
updated estimates of the 90-90-90 targets assist
programmes and organisations to track progress
and prioritise further programme implementation.
In eastern and southern Africa, where more than
half of global PLHIV [3,4] are resident, estimates of
the ‘first 90’ are derived from national population-
based surveys that include HIV serological testing
(henceforth termed ‘sero-surveys’) [5]. When the sur-
vey includes a question directly asking respondents to
report their last HIV test result, the estimate of the
‘first 90’ in the year of the survey is simply the
proportion of people who reported they were diag-
nosed with HIV at their last HIV test out of the total
number who tested HIV-positive in the survey. If the
survey does not include a direct question about the
knowledge of HIV status, such as Demographic and
Health Surveys (DHS) [6], the estimate of the ‘first
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90’ in the year of the survey is the average of two
indicators: (i) the percentage of people diagnosed
with HIV in the survey who report ever having
been tested for HIV and receiving their last test result
(upper bound), and (ii) the percentage of PLHIV on
ART as reported with national ART programme data
(lower bound) [5]. However, the accuracy of the
upper bound estimate may be affected by respondents
who are hesitant to report their HIV testing history,
or by the training and ability of the interviewers to
ask sensitive questions [1,7]. Thus, the current
UNAIDS estimation method for the ‘first 90’ could
potentially be sensitive to undisclosed HIV testing
history.
In this report, we used data from a health and
demographic surveillance site (HDSS) in northwest
Tanzania with population-based HIV sero-surveil-
lance and linked medical records to measure the
extent of undisclosed HIV testing history among
sero-survey participants who had attended a previous
sero-survey or had previously registered for HIV care
and treatment. We modelled associations with non-
disclosure of HIV testing history and stratified results
by HIV test result. Finally, we measured the discre-
pancy between an estimate of the ‘first 90’ using
survey data and an augmented estimate using linked
HIV testing history and medical records.
Methods
Data sources
The Kisesa observational HIV cohort study was estab-
lished in 1994 and is located in a rural ward in theMagu
district of Mwanza region in northwest Tanzania [8].
The study conducts annual or bi-annual rounds of
household-based demographic surveillance (31 to
date) and has completed 8 rounds of population-based
HIV sero-surveys. During a sero-survey round, all
adults aged 15 years or older living in the Kisesa
HDSS coverage area are invited to attend a temporary
village-based clinic for a personal interview and to give
a finger-prick blood specimen to be anonymously tested
for HIV. Beginning in 2007, voluntary HTC services
were offered at the sero-survey clinics to those who
wanted to know their HIV status, based on a second,
separate blood specimen for the HIV test. Sero-survey
records indicate whether the participant received their
test result. Participants’ records from all sero-survey
rounds are linked with a unique permanent identifier,
and temporary household-based identifiers from the
HDSS are also cross-referenced on each sero-survey
record. This analysis included all sero-survey partici-
pants in each of the three most recent rounds: Sero 6
(2010), Sero 7 (2013), and Sero 8 (2016).
A government-run health centre is located within
the Kisesa HDSS catchment area, including an HIV
care and treatment centre (CTC). The CTC databases
have been fully digitised, and data clerks regularly
update and run data checks on these data. Medical
records from the CTC have been linked to the HDSS
database using point-of-contact interactive record link-
age (PIRL), described elsewhere [9,10]. Ethical
approvals for each of the sero-survey rounds and the
PIRL study were obtained from the Tanzanian National
Institute for Medical Research Lake Zone Institutional
Review Board (MR/53/100/450) and the London School
of Hygiene & Tropical Medicine (8852). Informed writ-
ten consent was obtained from all participants.
Estimating the ‘first 90’
The Kisesa sero-surveys, akin to DHS, include indirect
questions about knowledge of HIV status by asking
about HIV testing history. To determine risk factors
associated with non-disclosure of HIV testing history,
the regression analyses only included participants with
evidence of a previous diagnostic HIV test. A previous
diagnostic test was determined by the linked sero-survey
records from all sero-survey rounds. We also considered
patients who had registered for care at the local HIV care
and treatment clinic to be diagnosed at the time of
registration or as noted in their medical records.
UNAIDS estimates the upper bound of the ‘first 90’
using the following two questions: (i) ‘Have you ever
had HIV testing and counselling?’; and (ii) ‘Did you
find out your test results after your last test?’ Those
who responded affirmatively to both questions were
classified as disclosing their HIV testing history. All
others were classified as having an undisclosed HIV
testing history.
Following UNAIDS guidelines [5], we estimated
the ‘first 90’ for each sero-survey round by averaging
the proportion of participants who tested HIV-posi-
tive who reported ever having been tested for HIV
and receiving their last test result (upper bound), and
the percentage of adult PLHIV on ART as reported
with national ART programme data (lower bound).
Estimates of the percentage of adult PLHIV on ART
for each year coinciding with a sero-survey round
were obtained from UNAIDS AIDSinfo [4]; however,
these were national estimates as longitudinal, sub-
national ART coverage estimates were not available.
In a sensitivity analysis to account for possible mis-
specification of ART coverage, we determined the
robustness of the estimates by increasing and decreas-
ing the national ART coverage estimates by half, and
by setting them to their theoretical maximum equal
to the upper bound.
Estimating impact
We updated the estimate of the ‘first 90’ by adding
information from the linked HIV testing history and
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medical records. For each sero-survey round, we cal-
culated two measures of the sensitivity of the
UNAIDS estimation method to undisclosed HIV test-
ing history:
absolute impact : Impactabs ¼ u^ o^ (1)
relative impact : impactrel ¼ ðu^ o^Þ=u^ (2)
where o^ is the original estimate of the ‘first 90’
using self-reported survey responses, and u^ is the
updated estimate of the ‘first 90’ by augmenting o^
with linked data.
Covariates
We extracted demographic, behavioural, and clinical
characteristics from each sero-survey round.
Demographic variables included sex, age, education
level (no primary, some primary, or primary or higher),
sub-village of residence (rural, peri-urban, or urban),
whether the sub-village of residence has a road, and
marital status (never or ever married/cohabitated).
Behavioural variables included the reported number of
sex partners in the last 12months and reported condom
use at last sex. Clinical variables included whether par-
ticipants visited a health provider (e.g. hospital, health
centre, dispensary, antenatal clinic, vaccination clinic,
visit from home-based care worker, private pharmacy,
or traditional healer) in the last 12 months, and for
those who tested HIV-positive, whether the participant
had initiated ART prior to the sero-survey as noted in
CTC records, and the time since HIV diagnosis using
the first HIV-positive test date in a sero-survey. For
individuals who did not have a recorded positive HIV
test date in a sero-survey, we used the first HIV-positive
test date as listed in their medical records.
Statistical analyses
Chi-square and Fisher’s exact tests were used to assess
differences between participants with and without a pre-
vious diagnostic HIV test, as well as between participants
who did and did not disclose their HIV testing history.
Some participants attended more than one sero-survey
round. Thus, generalised estimating equations (GEE)
logistic regression models were used to account for the
correlated data. We fitted crude and adjusted GEE logis-
tic regression models for all participants to detect differ-
ences in disclosure of HIV testing history by HIV test
result. We also fitted analogous models limited to parti-
cipants who tested HIV-positive during the sero-survey.
Statistical analyses were performed using SAS version 9.4
(SAS Institute Inc., Cary, NC, USA).
Results
Sample
There were 7981 participants (61% female) in Sero 6,
7607 participants (62% female) in Sero 7, and 7161 parti-
cipants (62% female) in Sero 8, of whom 860 (10.8%),
1232 (16.2%), and 1786 (24.9%) respectively had received
a diagnostic HIV test in a previous sero-survey round or
registered in the CTC (Figure 1). Among participants
who tested HIV-negative during a sero-survey, those
who had previously received a diagnostic HIV test (i.e.
repeatHIV-negative testers) were older, hadmore educa-
tion, were frommore urbanised areas, reported more sex
partners in the last 12 months, reported less condom use
at last sex, and reported more health service use than
those who had not previously received a diagnostics HIV
test (all p < 0.05) (see Supplemental Table 1). The differ-
ences between participants with and without a previous
HIV diagnostic test among people who tested HIV-posi-
tive during a survey were narrower (see Supplemental
Table 2), although this may be due to the smaller sample
size resulting in lower statistical power. In this group, the
only statistically significant difference found in multiple
survey rounds was that participants who had previously
received a diagnostic HIV test were frommore urbanised
areas than those who had not previously received a diag-
nostics HIV test (p < 0.04).
Non-disclosure of HIV testing history
Among participants with a previous diagnostic HIV
test and who tested HIV-positive in the sero-survey,
Figure 1. Study sample from three rounds of HIV serological surveys in Tanzania, by HIV status, 2010–2016.
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39/138 (28%) in Sero 6, 73/222 (33%) in Sero 7, and
64/275 (23%) in Sero 8 did not disclose their HIV
testing history. Among participants with a previous
diagnostic HIV test and who tested HIV-negative in
the sero-survey, 142/722 (20%) in Sero 6, 340/1010
(34%) in Sero 7, and 352/1511 (23%) in Sero 8 did
not disclose their HIV testing history. In bivariate
analyses, there was a statistically significant difference
between the level of non-disclosure of HIV testing
history by HIV test result in Sero 6 (p = 0.02), but not
in Sero 7 (p = 0.82) or Sero 8 (p = 0.99). In addition,
participants with less education and who reported not
knowing or who refused to report the number of sex
partners in the last 12 months were more likely to not
disclose their HIV testing history in all three sero-
survey rounds (all p < 0.03) (Table 1).
Regression models
After accounting for the correlated data, there was
no evidence that participants who tested HIV-
positive differentially disclosed their HIV testing
history compared to those who tested HIV-nega-
tive during a sero-survey (crude odds ratio [cOR]
1.10, 95% confidence interval [CI] 0.90, 1.34)
(Table 2). After adjusting for other covariates,
non-disclosure of HIV testing history was asso-
ciated with sex (females vs. males: adjusted odds
Table 1. Characteristics of survey participants with evidence of previous HIV testing, by disclosure of testing history.
Sero 6 (2010) Sero 7 (2013) Sero 8 (2016)
Disclosed
n = 679
Undisclosed
n = 181 p-value
Disclosed
n = 819
Undisclosed
n = 413 p-value
Disclosed
n = 1370
Undisclosed
n = 416 p-value
HIV test result in sero
HIV+ 99 (72) 39 (28) 0.023 149 (67) 73 (33) 0.824 211 (77) 64 (23) 0.993
HIV- 580 (80) 142 (20) 670 (66) 340 (34) 1159 (77) 352 (23)
Demographic characteristic
Sex
Female 407 (80) 103 (20) 0.482 470 (62) 292 (38) <0.001 854 (74) 297 (26) < 0.001
Male 270 (78) 77 (22) 349 (75) 117 (25) 516 (82) 115 (18)
Age, years
15–29 181 (79) 49 (21) 0.676 170 (64) 94 (36) 0.719 301 (72) 119 (28) 0.002
30–49 377 (80) 95 (20) 444 (67) 219 (33) 683 (80) 169 (20)
50+ 121 (77) 37 (23) 205 (67) 100 (33) 386 (75) 128 (25)
Education level
No primary 136 (70) 59 (30) 0.001 158 (51) 152 (49) < 0.001 315 (67) 158 (33) < 0.001
Some primary 88 (80) 22 (20) 97 (66) 51 (24) 156 (78) 43 (22)
Primary or higher 455 (82) 100 (18) 564 (73) 210 (27) 899 (81) 215 (19)
Sub-village of residence, type
Rural 355 (75) 119 (25) 0.005 352 (59) 242 (41) < 0.001 680 (76) 218 (24) 0.343
Peri-urban 184 (85) 33 (15) 234 (68) 110 (32) 358 (79) 94 (21)
Urban 140 (83) 29 (17) 233 (79) 61 (21) 332 (76) 104 (24)
Sub-village of residence, has road
No 399 (75) 133 (25) < 0.001 413 (60) 280 (40) < 0.001 762 (76) 243 (24) 0.315
Yes 280 (85) 48 (15) 406 (75) 133 (25) 608 (78) 173 (22)
Current marital status
Never married/cohabitated 66 (71) 27 (29) 0.045 88 (63) 52 (37) 0.335 145 (68) 69 (32) 0.001
Ever married/cohabitated 613 (80) 154 (20) 731 (67) 361 (33) 1225 (78) 347 (22)
Behavioural characteristic
Number of sex partners in last 12 months
Don’t know/refused 8 (44) 10 (56) 0.003 17 (46) 20 (54) < 0.001 46 (64) 26 (36) 0.028
0 90 (81) 21 (19) 102 (58) 74 (42) 202 (75) 66 (25)
1 462 (80) 116 (20) 599 (68) 288 (32) 1005 (77) 298 (23)
2 or more 119 (78) 34 (22) 101 (77) 31 (23) 117 (82) 26 (18)
Condom use at last sex
Don’t know/refused 96 (76) 31 (24) 0.424 619 (64) 347 (36) < 0.001 155 (69) 69 (31) 0.001
No 536 (79) 141 (21) 155 (72) 61 (28) 1133 (77) 336 (23)
Yes 47 (84) 9 (16) 45 (90) 5 (10) 82 (88) 11 (12)
Clinical characteristic
Visited health provider in last 12 months
No 84 (79) 22 (21) 0.937 105 (55) 86 (45) < 0.002 343 (71) 142 (29) < 0.001
Yes 595 (79) 159 (21) 714 (69) 327 (31) 1027 (79) 274 (21)
HIV+ only
Time since HIV diagnosis, years
First positive test during sero 23 (61) 15 (39) 0.220 34 (69) 15 (31) 0.036 30 (64) 17 (36) 0.109
<5 48 (73) 18 (27) 62 (62) 38 (38) 79 (77) 24 (23)
5–9 12 (86) 2 (14) 34 (64) 19 (36) 74 (81) 17 (19)
10+ 16 (80) 4 (20) 19 (95) 1 (5) 28 (82) 6 (18)
Initiated antiretroviral therapy
Yes 50 (79) 13 (21) 0.068 55 (66) 28 (34) 0.835 53 (75) 18 (25) 0.631
No 49 (65) 26 (35) 94 (68) 45 (32) 158 (77) 46 (23)
Abbreviations: HIV – human immunodeficiency virus; sero – HIV serological survey
Note: all statistics are given in n(row %); differences tested for significance with chi-square (χ2) and Fisher’s exact tests.
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ratio [aOR] 1.54, 95% CI 1.27, 1.88), education
(no primary vs. primary or higher: aOR 2.01,
95% CI 1.67, 2.41), marital status (never vs. ever
married/cohabitated: aOR 1.88, 95% CI 1.43, 2.47),
and reported condom use at last sex (do not
know/refused to answer vs. yes: aOR 2.93, 95%
CI 1.84, 4.67; no vs. yes: aOR 2.16, 95% CI 1.39,
3.36). There were no significant associations
between non-disclosure of HIV testing history
and age, sub-village of residence, and reported
number of sex partners in the last 12 months,
after adjusting for other covariates.
Among participants who tested HIV-positive dur-
ing the sero-survey, participants’ whose positive test
during the survey was their first had 3 times more
odds (aOR 3.03, 95% CI 1.39, 6.62) and those with a
first recorded diagnosis of less than 5 years had 2.4
times more odds (aOR 2.36, 95% CI 1.18, 4.69) to not
disclose their HIV testing history than their counter-
parts who had first been diagnosed over 10 years
prior to the survey. There was no evidence of an
association between non-disclosure of HIV testing
history and whether the participant was on ART
(aOR 1.08, 95% CI 0.72, 1.62).
Table 2. Associations with non-disclosure of HIV testing history among participants of population-based HIV serological surveys.
All participants, n = 2747 HIV+ only, n = 454
cOR (95% CI) aOR (95% CI) cOR (95% CI) aOR (95% CI)
HIV test result in any sero
HIV+ vs. HIV- 1.10 (0.90, 1.34) 1.08 (0.87, 1.34)
Sero round
Sero 8 1.11 (0.92, 1.34) 0.86 (0.66, 1.13) 0.76 (0.48, 1.20) 0.75 (0.45, 1.24)
Sero 7 1.87 (1.53, 2.27)*** 1.30 (0.95, 1.77) 1.22 (0.77, 1.94) 0.99 (0.55, 1.78)
Sero 6 1 1 1 1
HIV test result by sero round
HIV+ vs. HIV-, Sero 8 1.00 (0.74, 1.35) 0.94 (0.68, 1.30)
HIV+ vs. HIV-, Sero 7 0.95 (0.69, 1.29) 0.88 (0.64, 1.21)
HIV+ vs. HIV-, Sero 6 1.59 (1.06, 2.40)* 1.53 (0.99, 2.36)
Demographic characteristic
Sex
Female 1.46 (1.25, 1.71)*** 1.54 (1.27, 1.88)*** 1.38 (0.93, 2.04) 1.39 (0.87, 2.23)
Male 1 1 1 1
Age, years
15–29 1.25 (1.05, 1.48)* 1.18 (0.97, 1.44) 1.87 (1.22, 2.87)** 1.46 (0.92, 2.32)
30–49 1 1 1 1
50+ 1.15 (0.96, 1.38) 1.08 (0.88, 1.32) 1.36 (0.87, 2.12) 1.43 (0.89, 2.29)
Education level
No primary 2.19 (1.85, 2.58)*** 2.01 (1.67, 2.41)*** 1.65 (1.11, 2.44)* 1.36 (0.88, 2.10)
Some primary 1.23 (0.98, 1.56) 1.26 (0.99, 1.61) 1.24 (0.70, 2.19) 1.25 (0.68, 2.28)
Primary or higher 1 1 1 1
Sub-village of residence, type
Rural 1.50 (1.24, 1.81)*** 1.19 (0.89, 1.60) 1.47 (0.95, 2.27) 1.41 (0.66, 3.01)
Peri-urban 1.10 (0.88, 1.37) 0.94 (0.73, 1.22) 1.21 (0.74, 1.97) 1.01 (0.53, 1.92)
Urban 1 1 1 1
Sub-village of residence, has road
No 1.51 (1.30, 1.76)*** 1.35 (1.06, 1.72)* 1.27 (0.88, 1.82) 1.04 (0.55, 1.95)
Yes 1 1 1 1
Current marital status
Never married/cohabitated 1.48 (1.20, 1.83)*** 1.88 (1.43, 2.47)*** 1.77 (1.00, 3.15)* 1.46 (0.74, 2.89)
Ever married/cohabitated 1 1 1 1
Behavioural characteristic
Number of sex partners in last 12 months
Don’t know/refused 2.87 (1.88, 4.36)*** 1.32 (0.83, 2.08) 1.89 (0.67, 5.29) 0.99 (0.29, 3.39)
0 1.48 (1.10, 1.99)* 0.82 (0.56, 1.19) 1.10 (0.55, 2.21) 0.69 (0.27, 1.77)
1 1.25 (0.97, 1.59) 1.00 (0.75, 1.33) 1.08 (0.57, 2.05) 0.87 (0.39, 1.90)
2 or more 1 1 1 1
Condom use at last sex
Don’t know/refused 3.48 (2.29, 5.29)*** 2.93 (1.84, 4.67)*** 4.94 (1.50,16.31)** 4.46 (1.24,16.04)*
No 1.99 (1.32, 3.02)** 2.16 (1.39, 3.36)*** 3.71 (1.14,12.09)* 3.19 (0.91,11.14)
Yes 1 1 1 1
Clinical characteristic
Visited health provider in last 12 months
No 1.44 (1.21, 1.70)*** 1.50 (1.24, 1.80)*** 1.53 (0.96, 2.45) 1.70 (1.01, 2.85)*
Yes 1 1 1 1
HIV+ only
Times since HIV diagnosis, years
First positive test during sero 3.33 (1.61, 6.87)** 3.03 (1.39, 6.62)**
<5 2.65 (1.37, 5.13)* 2.36 (1.18, 4.69)*
5–9 1.86 (0.93, 3.75) 1.75 (0.84, 3.64)
10+ 1 1
Initiated antiretroviral therapy
Yes 1.01 (0.70, 1.47) 1.09 (0.72, 1.64)
No 1 1
Abbreviations: cOR – crude unadjusted odds ratio; aOR – adjusted odds ratio; CI – confidence interval; HIV – human immunodeficiency virus; sero – HIV
serological survey
*p < 0.05; **p < 0.01; ***p < 0.001
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Implications for the estimate of the ‘first 90’
The number of participants who tested HIV-positive
was 530 (6.6%) in Sero 6, 557 (7.3%) in Sero 7, and 490
(6.8%) in Sero 8. Of these, the number of participants
who reported having ever been tested for HIV and
received their last HIV test result (the upper bound of
the ‘first 90’ estimate) was 268 (50.6%) in Sero 6, 275
(49.4%) in Sero 7, and 328 (66.9%) in Sero 8. Estimates
of ART coverage (the lower bound of the ‘first 90’
estimate) in Tanzania for each year coinciding with
each sero-survey round were 18% in 2010, 39% in
2013, and 62% in 2016. Thus, cross-sectional estimates
of the ‘first 90’ using self-reported survey data com-
bined with the national ART estimates were 34.3% in
2010, 44.2% in 2013, and 64.5% in 2016 (Figure 2).
However, there was evidence from the linked records
that some patients who tested positive during the sero-
survey did not disclose their HIV testing history (39
participants in Sero 6, 70 participants in Sero 7, and 65
participants in Sero 8). After augmenting the estimates
of the upper bound with this information, the estimate
of the ‘first 90’ increased to 38.0% in 2010, 50.5% in
2013, and 71.1% in 2016. These increases corresponded
to an absolute impact in the ‘first 90’ of 3.7 percentage
points in Sero 6, 6.2 percentage points in Sero 7, and 6.7
percentage points in Sero 8, and a relative impact of
9.6% in Sero 6, 12.4% in Sero 7, and 9.4% in Sero 8.
In sensitivity analyses, decreasing estimates of
ART coverage by half resulted in increased estimates
of relative impact to 10.9% in Sero 6, 15.4% in Sero 7,
and 12.0% in Sero 8; increasing estimates of ART
coverage by 50% resulted in decreased estimates rela-
tive impact to 8.6% in Sero 6, 10.4% in Sero 7, and
7.7% in Sero 8; and setting the lower bound equal to
the upper bound resulted in the highest estimates of
relative impact to 12.6% in Sero 6, 20.2% in Sero 7,
and 16.6% in Sero 8.
Discussion
Due to non-disclosure of HIV testing history, self-
reported HIV testing history under-estimated the
‘first 90’ of the widely used UNAIDS 90-90-90 targets
by 9.4% to 12.4% between 2010 and 2016 in a rural
Tanzanian community. The size of the relative impact
was directly related to the proportion of participants
who did not disclose their HIV testing history – more
non-disclosures resulted in higher impact. In addi-
tion, our estimates of the number of individuals who
received a previous HIV diagnostic test or HIV care
are likely to be under-estimated since we did not
capture HIV testing that occurs outside the sero-
surveys or HIV care outside the Kisesa HDSS area.
Because self-reports of HIV diagnosis factor into the
current UNAIDS estimation of the ‘first 90’ they are
likely to be under-estimated, which may ultimately
affect our understanding of the gaps in HIV care and
treatment programmes and misallocate resources.
Other estimation methods that utilise self-reported
HIV testing history may be similarly affected.
The upper bound of the UNAIDS estimate of the
‘first 90’ (proportion reporting ever tested and receiv-
ing last test result) includes individuals who may
truly not know their HIV-positive status because the
last test result they received was negative (i.e. sero-
converters), which is why UNAIDS uses this as an
upper bound rather than a direct estimate of knowl-
edge of HIV status. The rationale for using ART
coverage as the lower bound is that the proportion
of PLHIV who are diagnosed (‘first 90’) cannot be
lower than the proportion of PLHIV receiving ART.
We found that changes in ART coverage drove the
increase in the ‘first 90’ over the study period as it
increased from 18% to 62% (a 224% relative change)
compared to an increase from 58% to 80% (a 39%
relative change) in the upper bound. While estimates
Figure 2. Impact of non-disclosure of HIV testing history on the proportion of PLHIV who know their status (the ‘first 90’ of the
UNAIDS 90-90-90 target) using population-based HIV serological survey data and linked clinic data in Kisesa, Tanzania, 2010–2016.
Note: the ‘first 90’ for each sero-survey round was estimated by averaging the proportion of participants who tested HIV-positive and reported
ever having been tested for HIV and receiving their last test result (upper bound), and the percentage of adult PLHIV on ART as reported with
national ART programme data (lower bound). The bars presented in this figure represent those bounds and are not estimations of error around
the ‘first 90’.
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of ART coverage were not available at the sub-
national level, we accounted for potential measure-
ment errors in sensitivity analyses and found that
setting ART coverage equal to the upper bound
increased the estimate of relative impact in the ‘first
90’ to 12.6–20.2% over the study period.
The proportion of PLHIV who reported knowing
their HIV sero-status doubled from 34% in 2010 to
65% in 2016 in this rural Tanzanian community.
There is a lack of longitudinal, national or sub-
national estimates of the ‘first 90’ or its components
available to which we can compare our findings.
UNAIDS has estimated that 70% of PLHIV in
Tanzania knew their sero-status in 2016 [3,4], which
is similar to our sub-national estimate in that year but
cannot be directly compared. A national survey con-
ducted by the National Bureau of Statistics in 2011
showed that 54.1% of those surveyed in the Mwanza
region had ever been tested for HIV and received
their last test result [11], which is reasonably consis-
tent with our finding of 50.6% of participants sur-
veyed in the 2010 survey.
There were substantial levels of non-disclosure ofHIV
testing history in this sample. Between 1 in 3 and 1 in 5
participants did not accurately report their HIV testing
history during a sero-survey. Interestingly, we did not
find any evidence that participants who tested HIV-
positive were more or less likely to disclose their HIV
testing history than those who tested HIV-negative after
adjusting for other factors. In unadjusted analyses, not
knowing or refusing to indicate the number of sex part-
ners in the last 12 months or condom use at last sex had
the highest associations with non-disclosure. In the
adjusted model, not knowing or refusing to indicate
whether a condom was used at last sex remained inde-
pendently associated with non-disclosure. Being pre-
pared to answer sensitive questions about sexual
behaviour may indicate a person’s willingness to be
open about other sensitive topics, such as HIV testing
history. Those who reported no condom use at last sex
were more likely to be female, which was also associated
with non-disclosure of HIV testing history. Several stu-
dies have shownwomen perceive and are targets of HIV-
related stigma more than men [12–15], which may
impede their willingness to discuss their testing history.
Similarly, it is plausible that some participants prefer to
deny that they have had an HIV test because the act of
testing – even if HIV-negative – may suggest perceived
risk and thus certain risk behaviours. In addition, the
women in our sample were significantly younger and
reported less education than men, both factors which
were associated with non-disclosure of HIV testing his-
tory. Even though women had higher participation rates
in the Kisesa sero-surveys than men, we hypothesise that
men who self-select to participate may be more comfor-
table discussing HIV testing history, and more broadly
that participation may not correlate with disclosure
equally among men and women. Finally, there is a
potential for recall bias among all participants since
sero-survey rounds are typically three years apart.
In a model limited to participants who tested HIV-
positive during a sero-survey, those who were first
diagnosed with HIV infection during the sero-survey
and those with a recent diagnosis of less than 5 years
were up to 3 times more likely to not disclose their HIV
infection compared to their counterparts who had lived
with HIV for at least 10 years prior to the survey. There
is some evidence among PLHIV in Tanzania that time
since HIV diagnosis is negatively correlated with inter-
nalised stigma [16], and that HIV-related stigma is
significantly associated with concealment of HIV status
[16,17]. Therefore, individuals who have been aware of
their positive HIV status for longer durations of time
may have come to terms with their HIV status and were
more comfortable to report their HIV testing history.
Our study had limitations. First, we were not able to
take into account the specificity of self-reporting.
However, if individuals reported testing when in fact
they have not, this would decrease the impact of non-
disclosure of testing history on the UNAIDS estimation
method. Further research identifying and measuring
the impact of false positives on the estimate of the
‘first 90’ will become possible as linkages between test-
ing facilities and sero-surveys continue to expand
within and around the Kisesa surveillance area.
Second, we had a relatively small sample size of
PLHIV and therefore lacked sufficient power to detect
significant associations with non-disclosure of HIV
testing history among PLHIV. Third, participation
rates in the sero-surveys have declined over time to
43% of eligible adults residing in the surveillance popu-
lation during the most recent survey in 2016. However,
all participants agreed to provide a blood spot for anon-
ymous HIV testing and 99% further opted to receive
their results. Individuals who choose to participate may
be differentially inclined to report HIV testing history
than those who do not participate. Comparative
research should be employed in other HDSS sites to
investigate how the corrective factor in the measure-
ment of the ‘first 90’ may vary between settings.
Conclusions
There was substantial non-disclosure of previous HIV
testing history in population-based surveys from
Tanzania, which resulted in an under-estimate of the
first UNAIDS 90-90-90 target between 9.4% and 12.4%.
There were likely previous HIV diagnostic tests not
captured in this analysis, and therefore the impact esti-
mates are likely to still be under-estimated. The factor
most associated with non-disclosure of HIV testing
history was refusing to answer other sensitive questions,
a finding that could potentially be used to augment
estimates of the ‘first 90’ derived from other
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population-based surveys that do not benefit from
linked HIV testing and medical records. Comparative
research should be employed in other HDSS sites that
benefit from linked HIV testing and clinical data to
investigate how the corrective factor may vary between
settings.
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